Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug from China's LaNova Medicines.Please watch the video at Investors.com - ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The company's adjusted earnings per share stood at 2.30 euros compared with 2.07 euros in the prior-year period. Merck made an after-tax profit of 812 million euros compared with 740 million in the ...

Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...

On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...

Zentalis Pharmaceuticals (ZNTL) announced changes to its executive leadership team to support the Company as it plans and executes ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...